Literature DB >> 25893459

ABO, alemtuzumab and allogeneic transplantation.

L Cooling1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25893459     DOI： 10.1038/bmt.2015.77

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  20 in total

1.  Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse.

Authors:  M Hoegh-Petersen; M A Amin; Y Liu; A Ugarte-Torres; T S Williamson; P J Podgorny; J A Russell; A Grigg; D Ritchie; J Storek
Journal:  Bone Marrow Transplant       Date:  2012-06-04       Impact factor: 5.483

Review 2.  NKT cells, Treg, and their interactions in bone marrow transplantation.

Authors:  Holbrook E Kohrt; Asha B Pillai; Robert Lowsky; Samuel Strober
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

3.  Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery.

Authors:  Frank Gärtner; Stefanie Hieke; Jürgen Finke; Hartmut Bertz
Journal:  Cytotherapy       Date:  2013-10       Impact factor: 5.414

4.  Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source.

Authors:  Nicolas Blin; Richard Traineau; Stéphanie Houssin; Régis Peffault de Latour; Anna Petropoulou; Marie Robin; Jérôme Larghero; Patricia Ribaud; Gérard Socié
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-29       Impact factor: 5.742

5.  Production of anti-ABO blood group antibodies after minor ABO-incompatible bone marrow transplantation in NOD/SCID/gamma(c)(null) mice.

Authors:  Hirofumi Tomita; Yasushi Fuchimoto; Takehiko Mori; Jun Kato; Tomoe Uemura; Makoto Handa; Hirofumi Tazawa; Hideki Ohdan; Shinichiro Okamoto; Tatsuo Kuroda
Journal:  Clin Transplant       Date:  2013-10-11       Impact factor: 2.863

Review 6.  Alemtuzumab for the prevention and treatment of graft-versus-host disease.

Authors:  Junya Kanda; Richard D Lopez; David A Rizzieri
Journal:  Int J Hematol       Date:  2011-03-03       Impact factor: 2.490

7.  Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT.

Authors:  C K Brierley; T J Littlewood; A J Peniket; R Gregg; J Ward; A Clark; A Parker; R Malladi; P Medd
Journal:  Bone Marrow Transplant       Date:  2015-04-13       Impact factor: 5.483

8.  Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect.

Authors:  M Mielcarek; W Leisenring; B Torok-Storb; R Storb
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

Review 9.  Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation.

Authors:  S D Rowley; M L Donato; P Bhattacharyya
Journal:  Bone Marrow Transplant       Date:  2011-09       Impact factor: 5.483

10.  Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program.

Authors:  Fumihiko Kimura; Ken Sato; Shinichi Kobayashi; Takashi Ikeda; Hiroshi Sao; Shinichiro Okamoto; Koichi Miyamura; Shinichiro Mori; Hideki Akiyama; Makoto Hirokawa; Hitoshi Ohto; Hiroshi Ashida; Kazuo Motoyoshi
Journal:  Haematologica       Date:  2008-10-02       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.